Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 1, 2015, Pages 107-113

  Tursi, Antonio ^a   Elisei, Walter ^b   Picchio, Marcello ^c   Forti, Giacomo ^d   Penna, Antonio ^e   Inchingolo, Cosimo Damiano ^f   Nenna, Rosanna ^f   Brandimarte, Giovanni ^g  

^a ASL BAT   (Italy)

^b ASL RMH   (Italy)

^c Hospital P Colombo   (Italy)

^d SANTA MARIA GORETTI HOSPITAL   (Italy)

^e SAN PAOLO HOSPITAL   (Italy)

^f Digestive Endoscopy Unit   (Italy)

^g Cristo Re Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ARTICLE; COLITIS; COLONOSCOPY; DISTAL COLITIS; FEMALE; FOLLOW UP; GEBOES HISTOLOGY SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; INTESTINE BIOPSY; LEFT SIDED COLITIS; MAINTENANCE THERAPY; MALE; OBSERVATIONAL STUDY; PANCOLITIS; PATHOLOGIST; REMISSION; RETROSPECTIVE STUDY; ULCERATIVE COLITIS;

EID: 84964291059     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.07.012     Document Type: Article

References (34)

1. Reinisch W., Van Assche G., Befrits R., et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 2012, 6:248-258.
2. Peyrin-Biroulet L., Ferrante M., Magro F., et al. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011, 5:477-483.
3. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
4. Hecht G.A. Inflammatory bowel disease-live transmission. N Engl J Med 2008, 358:528-530.
5. Armuzzi A., Pugliese D., Danese S., et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013, 19:1065-1072.
6. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
7. Hanauer S.B., Kirsner J.B. Treat the patient or treat the disease?. Dig Dis 2012, 30:400-403.
8. Wright R., Truelove S.R. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966, 11:847-857.
9. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
10. Riley S.A., Mani V., Goodman M.J., Dutt S., Herd M.E. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32:174-178.
11. Rubin D., Huo D., Hetzel J., et al. Increased degree of histological inflammation predicts colectomy and hospitalization in patients with ulcerative colitis. Gastroenterology 2012, 132:A19.
12. Burger D., Thomas S., Walsh A., et al. Depth of remission may not predict outcome of UC over 2 years. Gut 2011, 60:A133.
13. Baars J.E., Nuij V.J., Oldenburg B., et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012, 18:1634-1640.
14. Rosenberg L., Lawlor G.O., Zenlea T., et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2012, 19:779-784.
15. Rosenberg L., Nanda K.S., Zenlea T., et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013, 11:991-996.
16. Hassan C., Ierardi E., Burattini O., et al. Tumour necrosis factor-alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007, 39:811-817.
17. Fratila O.C., Craciun C. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. J Gastrointestin Liver Dis 2010, 19:147-153.
18. Geboes K., Riddell R., Ost A., et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000, 47:404-409.
19. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomised study. N Engl J Med 1987, 317:1625-1629.
20. Knight D.M., Trinh H., Le J., Siegel S., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF-antibody. Mol Immunol 1993, 30:1443-1453.
21. Villanacci V., Antonelli E., Geboes K., et al. Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J Gastroenterol 2013, 19:968-978.
22. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010, 16:338-346.
23. Mosli M.H., Feagan B.G., Sandborn W.J., et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflammatory Bowel Diseases 2014, 20:564-575.
24. Peyrin-Biroulet L., Bressenot A., Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis?. Clin Gastroenterol Hepatol 2014, 12:929-934.
25. Molander P., Sipponen T., Kemppainen H., et al. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis 2013, 7:730-735.
26. Colombel J.F., Louis E., Peyrin-Biroulet L., et al. Deep remission: a new concept?. Dig Dis 2012, 30(Suppl. 3):107-111.
27. Torres J., Billioud V., Sachar D.B., et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012, 18:1356-1363.
28. Lemmens B., Arjis I., Van Assche G., et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 2013, 19:1194-1201.
29. Baumgart D.C. Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when?. Dig Dis 2011, 29(Suppl. 1):32-35.
30. D'Haens G., Geboes K., Peeters M., et al. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol 1997, 92:1275-1279.
31. Mutinga M.L., Odze R.D., Wang H.H., et al. The clinical significance of right-sided colonic inflammation in patients with left-sided chronic ulcerative colitis. Inflamm Bowel Dis 2004, 10:215-219.
32. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
33. Solem C.A., Loftus E.V., Tremaine W.J., et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
34. D'Incà R., Dal Pont E., Di Leo V., et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007, 22:429-437.